These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 30619288

  • 1. Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells.
    Jiang L, Fang X, Wang H, Li D, Wang X.
    Front Immunol; 2018; 9():2927. PubMed ID: 30619288
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas.
    Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Nakayama N, Otsuki Y, Nakayama S, Miyazaki K.
    Br J Cancer; 2012 Jul 10; 107(2):300-7. PubMed ID: 22653145
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells.
    Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, Cubillos-Ruiz JR, Jacobs AC, Gonzalez JL, Weaver J, Fiering S, Conejo-Garcia JR.
    J Exp Med; 2012 Mar 12; 209(3):495-506. PubMed ID: 22351930
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Fatty acid synthase: A key driver of ovarian cancer metastasis and a promising therapeutic target.
    Ahmad N, Moton S, Kuttikrishnan S, Prabhu KS, Masoodi T, Ahmad S, Uddin S.
    Pathol Res Pract; 2024 Aug 12; 260():155465. PubMed ID: 39018927
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer.
    Zaytseva YY, Rychahou PG, Gulhati P, Elliott VA, Mustain WC, O'Connor K, Morris AJ, Sunkara M, Weiss HL, Lee EY, Evers BM.
    Cancer Res; 2012 Mar 15; 72(6):1504-17. PubMed ID: 22266115
    [Abstract] [Full Text] [Related]

  • 14. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.
    Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, Martinez DG, Engle X, Gewirtz AT, Ahonen CL, Conejo-Garcia JR.
    Cancer Res; 2009 Sep 15; 69(18):7329-37. PubMed ID: 19738057
    [Abstract] [Full Text] [Related]

  • 15. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
    Goswami S, Sharma-Walia N.
    Oncotarget; 2016 Sep 13; 7(37):58953-58974. PubMed ID: 27270654
    [Abstract] [Full Text] [Related]

  • 16. Fatty acid synthase is a prognostic marker and associated with immune infiltrating in gastric cancers precision medicine.
    Zhou Y, Su W, Liu H, Chen T, Höti N, Pei H, Zhu H.
    Biomark Med; 2020 Feb 13; 14(3):185-199. PubMed ID: 31904263
    [Abstract] [Full Text] [Related]

  • 17. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.
    Veigel D, Wagner R, Stübiger G, Wuczkowski M, Filipits M, Horvat R, Benhamú B, López-Rodríguez ML, Leisser A, Valent P, Grusch M, Hegardt FG, García J, Serra D, Auersperg N, Colomer R, Grunt TW.
    Int J Cancer; 2015 May 01; 136(9):2078-90. PubMed ID: 25302649
    [Abstract] [Full Text] [Related]

  • 18. Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells.
    Zhong M, Zhong C, Cui W, Wang G, Zheng G, Li L, Zhang J, Ren R, Gao H, Wang T, Li X, Che J, Gohda E.
    BMC Cancer; 2019 May 14; 19(1):439. PubMed ID: 31088527
    [Abstract] [Full Text] [Related]

  • 19. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer.
    Bauerschlag DO, Maass N, Leonhardt P, Verburg FA, Pecks U, Zeppernick F, Morgenroth A, Mottaghy FM, Tolba R, Meinhold-Heerlein I, Bräutigam K.
    J Transl Med; 2015 May 07; 13():146. PubMed ID: 25947066
    [Abstract] [Full Text] [Related]

  • 20. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.
    Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis TC, Ruotsalainen JJ, Gaffal E, Landsberg J, Ludwig KU, Wilhelm C, Riek-Burchardt M, Müller AJ, Gebhardt C, Scolyer RA, Long GV, Janzen V, Teng MWL, Kastenmüller W, Mazzone M, Smyth MJ, Tüting T, Hölzel M.
    Immunity; 2017 Oct 17; 47(4):789-802.e9. PubMed ID: 29045907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.